Logo-jnp
J Nephropathol. 2016;5(2): 79-83. doi: 10.15171/jnp.2016.14
PMID: 27152294        PMCID: PMC4844913

Case Report

Acute oxalate nephropathy associated with orlistat

Youshay Humayun 1 * , Kenneth C. Ball 1, Jack R. Lewin 2, Anna A. Lerant 3,4, Tibor Fülöp 1

Cited by CrossRef: 8

1- Lumlertgul N, Siribamrungwong M, Jaber B, Susantitaphong P. Secondary Oxalate Nephropathy: A Systematic Review. Kidney International Reports. 2018;3(6):1363 [Crossref]
2- Zhang X, Pawar A, Greene E. 72-Year-Old Woman With Fatigue, Confusion, and Severe Acute Renal Failure. Mayo Clinic Proceedings. 2018;93(10):1520 [Crossref]
3- Bargagli M, Tio M, Waikar S, Ferraro P. Dietary Oxalate Intake and Kidney Outcomes. Nutrients. 2020;12(9):2673 [Crossref]
4- Afshan S, Farah Musa A, Echols V, Lerant A, Fülöp T. Persisting Hypocalcemia After Surgical Parathyroidectomy: The Differential Effectiveness of Calcium Citrate Versus Calcium Carbonate With Acid Suppression. The American Journal of the Medical Sciences. 2017;353(1):82 [Crossref]
5- Solomon L, Nixon A, Ogden L, Nair B. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Reports. 2017;:bcr-2016-218623 [Crossref]
6- Pilitsi E, Farr O, Polyzos S, Perakakis N, Nolen-Doerr E, Papathanasiou A, Mantzoros C. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism. 2019;92:170 [Crossref]
7- Gotthardt J, Bello N. Can we win the war on obesity with pharmacotherapy?. Expert Review of Clinical Pharmacology. 2016;9(10):1289 [Crossref]